A trial investigating the safety and efficacy of the drug combination Sofosbuvir/Velpatasvir/GS-9857 for 8 weeks against Sofosbuvir/Velpatasvir for 12 weeks for subjects with hepatitis C To compare the efficacy of treatment with sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed dose combination (FDC) for 8 weeks with that of SOF/VEL FDC for 12 weeks as measured by the proportion of sub...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study to provide idelalisib to subjects previously treated with GS-9820 The primary objective of this study is to provide idelalisib to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase 1 study to evaluate GS-5829 alone and in combination with enzalutamide in patients with metastatic castrate-resistant prostate cancer Dose Escalation: Characterize the safety/tolerability of GS-5829 as a single agent and in combination with enzalutamide (enz) in subjects with mCRPC; determine the MTD of GS-5829 as a single agent and...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic The primary objective of this study is to evaluate the long-term safety of darusentan in subjects with RHTN despite treatment with full doses of three or more antihypertensive medications, including a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The purpose of this study is to test the effectiveness of switching from ABC/3TC to F/TAF FDC versus continuing on ABC/3TC in HIV-1 infected subjects who are virologically suppressed. The safety and how well both the F/TAF FDC and ABC/3TC are tolerated will also be evaluated To evaluate the efficacy of switching ABC/3TC to F/TAF versus maintaining ABC/3TC in HIV-1 infected subjects who are virologically suppressed on regimens containing ABC/3TC as determined by the propor...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A long-term study to follow patients infected with chronic Hepatitis C who achieved a cure following treatment in a Gilead clinical trial To assess the durability of sustained virologic response (SVR) following treatment in a Gilead-sponsored Hepatitis C Study

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study for Efficacy and Tolerability of Entospletinib in Combination with Corticosteroids as First-Line Therapy in (cGVHD) To evaluate the effect of ENTO on the best overall response rate (BORR) as assessed by the NIH cGVHD Activity Assessment (NCAA) by 24 weeks in the setting of add-on to systemic corticosteroids as part...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to test the safety, tolerability and ability to maintain HIV suppression of switching from a tenofovir disoproxil fumarate (TDF) containing regimen to elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in the HIV-1 infected subjects aged ≥ 60 years who are virologically suppressed -To evaluate the safety of E/C/F/TAF relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone mineral density (BMD) measured at Week 48 in virologically-suppressed, H...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

GS-US-312-0115 : Essai de phase 3 randomisé, en double-aveugle, visant à évaluer l’efficacité et la tolérance de l’idélalisib associé à du bendamustine et du rituximab, chez des patients ayant une leucémie lymphoïde chronique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’idélalisib en association avec du bendamustine et du rituximab, chez des patients ayant une leucémie lymphoïde chronique. Les p...

• Pays France
• Organes Leucémies chroniques
• Spécialités Chimiothérapie, Thérapies Ciblées

A study to test the safety, tolerability and how well viral suppression is maintained of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) in HIV-1 infected subjects who are virologically suppressed and harbor the archived isolated NRTI resistance mutation M184V/M184I. Estudio para probar la seguridad, tolerabilidad y mantenimiento de la supresión viral al cambiar a una combinación de dosis fija (CDF) de elvitegravir / cobicistat / emtricitabina / tenofovir alafenamide (E/C/F/TAF) en sujetos infectados por VIH-1 que estén virológicamente suprimidosportadores de la mutación aislada y archivada M184V/M184I de resistencia a los ITIAN To evaluate the efficacy of E/C/F/TAF fixed dose combination (FDC) after switching from a stable regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent in maintaining HIV-1 RNA < 5...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune